Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company, has promoted Natarajan Sethuraman, PhD, to President of Research and Development. Dr. Sethuraman, previously the Chief Scientific Officer, has been with Entrada since its inception and has played a important role in advancing the company's ENTR-601-44 program into clinical trials. His leadership has been instrumental in building Entrada's pipeline of proprietary intracellular therapeutics.
CEO Dipal Doshi praised Dr. Sethuraman's contributions, highlighting his experience in end-to-end therapeutics development. Dr. Sethuraman expressed excitement about Entrada's approach to intracellular therapeutics and the potential to reach previously inaccessible targets. He joined Entrada in 2017 and has since led global research and clinical development, building an R&D team advancing a portfolio of programs from discovery through clinical development.
Entrada Therapeutics, Inc. (Nasdaq: TRDA), un'azienda biofarmaceutica in fase clinica, ha nominato Natarajan Sethuraman, PhD, Presidente Ricerca e Sviluppo. Il Dr. Sethuraman, precedentemente Chief Scientific Officer, è stato con Entrada sin dalla sua nascita e ha svolto un ruolo fondamentale nell'avanzamento del programma ENTR-601-44 verso le sperimentazioni cliniche. La sua leadership è stata determinante nella costruzione del portafoglio di terapie intracellulari proprietarie di Entrada.
Il CEO Dipal Doshi ha lodato i contributi del Dr. Sethuraman, evidenziando la sua esperienza nello sviluppo di terapie end-to-end. Il Dr. Sethuraman ha espresso entusiasmo per l'approccio di Entrada alle terapie intracellulari e il potenziale di raggiungere obiettivi precedentemente inaccessibili. È entrato in Entrada nel 2017 e da allora ha guidato la ricerca globale e lo sviluppo clinico, costruendo un team di R&D che avanza un portafoglio di programmi dalla scoperta fino allo sviluppo clinico.
Entrada Therapeutics, Inc. (Nasdaq: TRDA), una compañía biofarmacéutica en etapa clínica, ha promovido a Natarajan Sethuraman, PhD, como Presidente de Investigación y Desarrollo. El Dr. Sethuraman, anteriormente Chief Scientific Officer, ha estado con Entrada desde su fundación y ha desempeñado un papel importante en el avance del programa ENTR-601-44 hacia ensayos clínicos. Su liderazgo ha sido fundamental para construir el portafolio de terapias intracelulares propietarias de Entrada.
El CEO Dipal Doshi elogió las contribuciones del Dr. Sethuraman, destacando su experiencia en el desarrollo de terapias de extremo a extremo. El Dr. Sethuraman expresó su entusiasmo por el enfoque de Entrada hacia las terapias intracelulares y el potencial de alcanzar objetivos previamente inalcanzables. Se unió a Entrada en 2017 y desde entonces ha liderado la investigación global y el desarrollo clínico, formando un equipo de I+D que avanza un portafolio de programas desde el descubrimiento hasta el desarrollo clínico.
Entrada Therapeutics, Inc. (Nasdaq: TRDA), 임상 단계의 생명공학 회사가 Natarajan Sethuraman, PhD,를 연구 및 개발의 사장으로 승진시켰습니다. Sethuraman 박사는 이전에 최고 과학 책임자였으며 Entrada와 함께한 이래로 회사의 ENTR-601-44 프로그램을 임상 시험으로 발전시키는 데 중요한 역할을 했습니다. 그의 리더십은 Entrada의 독점적인 세포 내 치료법 파이프라인 구축에 결정적이었습니다.
CEO Dipal Doshi는 Sethuraman 박사의 기여를 칭찬하며 끝에서 끝까지의 치료법 개발에 대한 그의 경험을 강조했습니다. Sethuraman 박사는 Entrada의 세포 내 치료법 접근 방식과 이전에 접근할 수 없던 목표를 도달할 수 있는 가능성에 대해 흥분을 표했습니다. 그는 2017년에 Entrada에 합류하여 이후 글로벌 연구 및 임상 개발을 이끌며 발견부터 임상 개발까지의 프로그램 포트폴리오를 발전시키는 R&D 팀을 구성했습니다.
Entrada Therapeutics, Inc. (Nasdaq: TRDA), une entreprise biopharmaceutique en phase clinique, a promu Natarajan Sethuraman, PhD, au poste de Président de la Recherche et du Développement. Le Dr Sethuraman, ancien Chief Scientific Officer, fait partie d'Entrada depuis ses débuts et a joué un rôle clé dans l'avancement du programme ENTR-601-44 vers les essais cliniques. Son leadership a été essentiel pour construire le pipeline de thérapies intracellulaires propriétaires d'Entrada.
Le PDG Dipal Doshi a salué les contributions du Dr Sethuraman, en mettant en avant son expérience dans le développement de thérapies de bout en bout. Le Dr Sethuraman a exprimé son enthousiasme pour l'approche d'Entrada en matière de thérapies intracellulaires et le potentiel d'atteindre des cibles auparavant inaccessibles. Il a rejoint Entrada en 2017 et depuis lors, il a dirigé la recherche et le développement clinique à l'échelle mondiale, constituant une équipe de R&D qui fait progresser un portefeuille de programmes de la découverte au développement clinique.
Entrada Therapeutics, Inc. (Nasdaq: TRDA), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat Natarajan Sethuraman, PhD, zum Präsidenten für Forschung und Entwicklung befördert. Dr. Sethuraman, der zuvor Chief Scientific Officer war, ist seit der Gründung von Entrada tätig und hat eine wichtige Rolle bei der Fortschritt des ENTR-601-44-Programms in klinische Studien gespielt. Seine Führung war entscheidend für den Aufbau von Entradas Pipeline im Bereich proprietäre intrazelluläre Therapeutika.
CEO Dipal Doshi lobte die Beiträge von Dr. Sethuraman und hob seine Erfahrung in der vollständigen Entwicklung von Therapeutika hervor. Dr. Sethuraman äußerte seine Begeisterung für Entradas Ansatz zu intrazellulären Therapeutika und das Potenzial, zuvor unerreichbare Ziele zu erreichen. Er trat 2017 Entrada bei und führte seitdem die globale Forschung und klinische Entwicklung und entwickelte ein R&D-Team, das ein Portfolio von Programmen von der Entdeckung bis zur klinischen Entwicklung vorantreibt.
- Promotion of experienced leader Dr. Sethuraman to President of R&D
- Advancement of ENTR-601-44 program into clinical trials
- Development of a diverse pipeline of proprietary intracellular therapeutics
- None.
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately.
“Natarajan has been with Entrada since our inception and his leadership has been invaluable in the research and clinical development of the company’s diverse pipeline of proprietary intracellular therapeutics,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “His deep and broad experience in end-to-end therapeutics development has helped advance our ENTR-601-44 program into the clinic, build our pipeline, and establish a dedicated team driven by intellectual curiosity, teamwork and a commitment to patients and their families.”
"From the moment I joined Entrada, I have been excited by the versatility of our differentiated approach to intracellular therapeutics, and the potential to reach targets that have long been considered inaccessible,” said Dr. Sethuraman. “I am tremendously proud of the amazing progress of our team and look forward to advancing our clinical pipeline to positively impact the lives of patients and their families."
Dr. Sethuraman joined Entrada Therapeutics as Chief Scientific Officer in 2017 and leads global research and clinical development. He brings deep experience in drug discovery and development across multiple modalities including oligonucleotides, antibodies, therapeutic enzymes, and peptides. Under his leadership, Entrada has built an R&D team that is advancing an expansive portfolio of proprietary programs from discovery through clinical development. Prior to Entrada, Dr. Sethuraman was at Merck & Co., Inc. where he led the GlycoFi site as well as the research and development of novel biologics following Merck’s acquisition of GlycoFi in 2006. He holds a PhD in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute, a BSc from Tamil Nadu Agricultural University and completed his post-doctoral training at Duke University.
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4db2ccbc-a23f-48bd-bed9-edd834037fa6
FAQ
Who was promoted to President of Research and Development at Entrada Therapeutics (TRDA)?
What is Entrada Therapeutics' (TRDA) main focus in drug development?
Which Entrada Therapeutics (TRDA) program has advanced to clinical trials?
When did Dr. Sethuraman join Entrada Therapeutics (TRDA)?
